Table 8. Summary						
Indication	Ertapenem	Ampicillin/ sulbactam	Piperacillin/ tazobactam	Ticarcillin/ clavulanate	Imipenem/ cilastatin	Cefotaxime + metronidazole
Mechanism of action	Inhibition of PBP	Inhibition of PBP	Inhibition of PBP	Inhibition of PBP	Inhibition of PBP	Inhibition of PBP
Indications	4	3	6	7	8	11
Selected in vitro activity	_	• Clostridium difficile	<ul> <li>Pseudomonas aeruginosa</li> <li>Enterococcus faecalis</li> </ul>	• Pseudomonas aeruginosa	<ul> <li>Pseudomonas aeruginosa</li> <li>Enterococcus faecalis</li> <li>Clostridium difficile</li> </ul>	• Clostridium difficile
Dosing schedule	QD	QID	QID	QID	QID	TID-QID
Drug interactions	Lowest	Low	High	Intermediate	Intermediate	High
Dose adjustments in renal /hepatic impairment	Yes/No	Yes/No	Yes/No	Yes/No	Yes/No	Yes/Yes
Pediatric use	Not recommended	Yes	Safety and efficacy not established	Yes	Yes	Yes
Pregnancy	В	В	В	В	С	B if not 1st trimester
Projected cost savings or losses with ertapenem use	_	Lose money	Save money	Save money	Save money	Lose money